Insider Buying: Savara Inc (NASDAQ:SVRA) Director Purchases 50,000 Shares of Stock

Savara Inc (NASDAQ:SVRA – Get Rating) Director David A. Ramsay bought 50,000 shares of Savara stock in a transaction dated Wednesday, May 24th. The stock was acquired at an average cost of $2.56 per share, with a total value of $128,000.00. Following the transaction, the director now owns 2,151,142 shares of the company’s stock, valued at approximately $5,506,923.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Savara Stock Performance

NASDAQ SVRA traded up $0.07 during trading on Friday, hitting $2.65. 164,645 shares of the company’s stock were exchanged, compared to its average volume of 231,150. The company has a quick ratio of 23.90, a current ratio of 23.90 and a debt-to-equity ratio of 0.27. Savara Inc has a fifty-two week low of $1.08 and a fifty-two week high of $2.85. The stock’s 50 day moving average price is $1.98 and its two-hundred day moving average price is $1.95.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SVRA. Jane Street Group LLC acquired a new position in Savara during the third quarter worth about $26,000. Squarepoint Ops LLC acquired a new position in Savara during the first quarter worth about $32,000. Citigroup Inc. acquired a new position in Savara during the fourth quarter worth about $33,000. Barclays PLC increased its stake in shares of Savara by 490,960.0% in the first quarter. Barclays PLC now owns 24,553 shares of the company’s stock valued at $48,000 after buying an additional 24,548 shares during the period. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Savara in the first quarter valued at approximately $52,000. Institutional investors and hedge funds own 75.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SVRA. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Savara in a research report on Tuesday, April 4th. Jefferies Financial Group raised shares of Savara from a “hold” rating to a “buy” rating and upped their price objective for the stock from $2.00 to $4.00 in a research report on Tuesday, May 16th.

About Savara

(Get Rating)

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.